Last reviewed · How we verify

NCT03613480: QOLNAFLD

Quality of Life in Non-alcoholic Fatty Liver Disease (QOLNAFLD)

Status unknown NA Last updated 2 June 2022
What this trial tests

NA trial testing Motivational Interviewing in Non-Alcoholic Fatty Liver Disease in 100 participants. Status unknown.

Timeline
1 September 2018
Primary endpoint
31 December 2020
1 December 2022

Quick facts

Lead sponsorUniversity Hospital of Patras
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 September 2018
Primary completion31 December 2020
Estimated completion1 December 2022
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital of Patras

Who can join

18 and older, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent disorder which is directly linked to lifestyle patterns and is associated with poor quality of life, increased fatigue and psychological distress. The aim of the current study is to evaluate quality of life, fatigue and psychological functioning in NAFLD patients and assess the impact of systematic counseling on patients' psychosocial functioning.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Motivational Interviewing

Trials testing the same drug.

Other recruiting trials for Non-Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

Other University Hospital of Patras trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing